Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer.

Folprecht G.

Cancer Commun (Lond). 2019 Nov 14;39(1):74. doi: 10.1186/s40880-019-0417-1. No abstract available.

2.

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Buder-Bakhaya K, Hassel JC.

Front Immunol. 2018 Jun 28;9:1474. doi: 10.3389/fimmu.2018.01474. eCollection 2018. Review.

3.

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.

Tran PN, Sarkissian S, Chao J, Klempner SJ.

Gastrointest Cancer. 2017;7:1-11. doi: 10.2147/GICTT.S113525. Epub 2017 May 5.

Supplemental Content

Loading ...
Support Center